Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma - Authors' replys

Affiliations

¹ Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, South Korea. Electronic address: kyunghunlee@snu.ac.kr.
² Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Comment

Kyung-Hun Lee et al. Lancet Oncol. 2020 Sep.

. 2020 Sep;21(9):e413.

doi: 10.1016/S1470-2045(20)30476-9.

¹ Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, South Korea. Electronic address: kyunghunlee@snu.ac.kr.
² Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

No abstract available

Comment on

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, Wang Y, He AR, Lee KH; GO30140 investigators. Lee MS, et al. Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X. Lancet Oncol. 2020. PMID: 32502443 Clinical Trial.
Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Yang X, Wang D, Lin J, Yang X, Zhao H. Yang X, et al. Lancet Oncol. 2020 Sep;21(9):e412. doi: 10.1016/S1470-2045(20)30430-7. Lancet Oncol. 2020. PMID: 32888462 No abstract available.